Navigation

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel) [ID523]

Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2 positive metastatic or locally recurrent unresectable breast cancer, which has not been previously treated, or has relapsed after adjuvant therapy

Status: In development
Expected date of issue: TBC
Referral date: July 2012
Process: STA
Notes:

Scoped as part of Batch 23

Topic area:
 

NICE project team

Executive Lead: TBC
Technical Lead: Pilar Pinilla-Dominguez
Communications manager: Laura Gibson
Project manager:

Bijal Joshi

Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 28 March 2013
1st appraisal committee meeting: 09 July 2013
2nd appraisal committee meeting 04 September 2013
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

 

Manufacturers/sponsors

  • Roche Products (pertuzumab)

Patient/carer groups

  • Breakthrough Breast Cancer
  • Breast Cancer Campaign
  • Breast Cancer Care

Professional groups

  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • Pan-Lancashire PCT Cluster
  • Welsh Government

 

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland

Comparator manufacturers

  • None

Relevant research groups

Evidence Review Group

  • Liverpool Reviews & Implementation Group, University of Liverpool
  • National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

  • National Collaborating Centre for Cancer

Associated Public Health Groups

None

Top


 

Project history

Date Update
14 October 2013

Please note that there has been a delay for the release of the Final Appraisal Determination (FAD) for this appraisal. Noting the manufacturer’s comment that it is not possible to set a price at which pertuzumab would meet current acceptability criteria for cost effectiveness, the Institute’s Guidance Executive has asked the technology appraisals team to explore this further with a view to resolving the issue.

 

We will update this webpage with further information once we have considered the options for proceeding with this additional work.

Top


 

Key documents

This page was last updated: 16 April 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.